[{"id":"e7cf2c99-6cfe-4015-9ca9-b9a242d379a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04739813","created_at":"2021-02-05T13:56:26.764Z","updated_at":"2025-02-25T16:38:14.078Z","phase":"Phase 1","brief_title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT04739813","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6 • UGT1A1","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation","tags":["BCL2 • BCL6 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/09/2021","start_date":" 07/09/2021","primary_txt":" Primary completion: 10/29/2025","primary_completion_date":" 10/29/2025","study_txt":" Completion: 10/29/2030","study_completion_date":" 10/29/2030","last_update_posted":"2025-02-06"},{"id":"8e4c392a-1d29-432d-a4da-6bb8e1258676","acronym":"AG120-221-C-001","url":"https://clinicaltrials.gov/study/NCT02632708","created_at":"2021-01-17T17:12:58.212Z","updated_at":"2025-02-25T14:36:02.501Z","phase":"Phase 1","brief_title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","source_id_and_acronym":"NCT02632708 - AG120-221-C-001","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation","tags":["IDH1 • IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • Tibsovo (ivosidenib) • daunorubicin • idarubicin hydrochloride • Idhifa (enasidenib) • mitoxantrone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 12/31/2015","start_date":" 12/31/2015","primary_txt":" Primary completion: 12/13/2018","primary_completion_date":" 12/13/2018","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-07-25"},{"id":"64c0eae1-673c-4049-a5b1-8479f1fe1ac9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05683171","created_at":"2023-01-13T15:59:24.110Z","updated_at":"2024-07-02T16:35:04.648Z","phase":"Phase 1/2","brief_title":"A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma","source_id_and_acronym":"NCT05683171","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1 • UGT1A1 mutation","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Ezharmia (valemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-09"},{"id":"66937713-e1c8-4e82-bb66-47047e56b479","acronym":"IDHENTIFY","url":"https://clinicaltrials.gov/study/NCT02577406","created_at":"2021-03-25T18:30:43.571Z","updated_at":"2024-07-02T16:35:06.839Z","phase":"Phase 3","brief_title":"An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation","source_id_and_acronym":"NCT02577406 - IDHENTIFY","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • Idhifa (enasidenib) • hydroxyurea"],"overall_status":"Completed","enrollment":" Enrollment 319","initiation":"Initiation: 12/30/2015","start_date":" 12/30/2015","primary_txt":" Primary completion: 03/17/2020","primary_completion_date":" 03/17/2020","study_txt":" Completion: 03/25/2024","study_completion_date":" 03/25/2024","last_update_posted":"2024-04-30"},{"id":"11040b56-b83a-40c8-b335-611302ea384f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03720366","created_at":"2021-01-18T18:14:03.989Z","updated_at":"2024-07-02T16:35:17.394Z","phase":"Phase 1","brief_title":"A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients","source_id_and_acronym":"NCT03720366","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib) • midazolam hydrochloride • omeprazole"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 09/22/2023","primary_completion_date":" 09/22/2023","study_txt":" Completion: 12/22/2023","study_completion_date":" 12/22/2023","last_update_posted":"2024-02-28"},{"id":"98b146c5-bd25-418a-a86a-b48aaa091bb5","acronym":"AG-221-C-001","url":"https://clinicaltrials.gov/study/NCT01915498","created_at":"2021-01-17T17:36:57.841Z","updated_at":"2024-07-02T16:35:19.804Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation","source_id_and_acronym":"NCT01915498 - AG-221-C-001","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 345","initiation":"Initiation: 08/27/2013","start_date":" 08/27/2013","primary_txt":" Primary completion: 07/25/2019","primary_completion_date":" 07/25/2019","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2024-02-12"},{"id":"ec44533f-4eb5-491d-92bc-8c763456a04b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06010888","created_at":"2023-08-25T15:08:21.578Z","updated_at":"2024-07-02T16:35:39.030Z","phase":"Phase 2","brief_title":"Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC","source_id_and_acronym":"NCT06010888","lead_sponsor":"Fudan University","biomarkers":" BRAF • UGT1A1","pipe":" | ","alterations":" BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation","tags":["BRAF • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2023-08-25"},{"id":"e06060ec-f7b3-4249-8f3e-8a3fa8a80f7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05969899","created_at":"2023-08-01T15:10:04.615Z","updated_at":"2024-07-02T16:35:41.432Z","phase":"Phase 2","brief_title":"Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer","source_id_and_acronym":"NCT05969899","lead_sponsor":"Fudan University","biomarkers":" BRAF • UGT1A1","pipe":" | ","alterations":" BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation","tags":["BRAF • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/10/2023","start_date":" 07/10/2023","primary_txt":" Primary completion: 07/10/2024","primary_completion_date":" 07/10/2024","study_txt":" Completion: 02/10/2027","study_completion_date":" 02/10/2027","last_update_posted":"2023-08-01"},{"id":"da0aba2e-1cdd-4bb3-b3f5-17acd4cb3848","acronym":"","url":"https://clinicaltrials.gov/study/NCT04250051","created_at":"2021-01-18T20:39:12.207Z","updated_at":"2024-07-02T16:35:48.026Z","phase":"Phase 1","brief_title":"Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04250051","lead_sponsor":"Northwestern University","biomarkers":" IDH1 • UGT1A1","pipe":" | ","alterations":" IDH1 R132 • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH1 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132 • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Tibsovo (ivosidenib) • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 12/21/2020","start_date":" 12/21/2020","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2023-05-15"},{"id":"fecf6843-8422-4be0-ad2d-bbf921311b94","acronym":"HOVON150AML","url":"https://clinicaltrials.gov/study/NCT03839771","created_at":"2021-01-18T18:57:21.726Z","updated_at":"2024-07-02T16:36:24.976Z","phase":"Phase 3","brief_title":"A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy","source_id_and_acronym":"NCT03839771 - HOVON150AML","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" FLT3 • IDH1 • IDH2 • UGT1A1","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • FLT3 mutation • IDH1 R132 • UGT1A1*1*1 • FLT3 mutation + IDH1 mutation • IDH2 R140 • IDH2 R172 • UGT1A1 mutation","tags":["FLT3 • IDH1 • IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • FLT3 mutation • IDH1 R132 • UGT1A1*1*1 • FLT3 mutation + IDH1 mutation • IDH2 R140 • IDH2 R172 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 968","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2033","study_completion_date":" 03/01/2033","last_update_posted":"2021-09-01"},{"id":"a1087211-347a-4460-946c-85e3dc0c74dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04806659","created_at":"2021-03-19T15:59:03.686Z","updated_at":"2024-07-02T16:36:33.044Z","phase":"Phase 1","brief_title":"A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia","source_id_and_acronym":"NCT04806659","lead_sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SH1573"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 08/04/2020","start_date":" 08/04/2020","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2021-03-19"},{"id":"ec969d34-99e2-44dd-a268-74c386650639","acronym":"","url":"https://clinicaltrials.gov/study/NCT02273739","created_at":"2021-01-18T10:41:52.200Z","updated_at":"2024-07-02T16:36:34.196Z","phase":"Phase 1/2","brief_title":"Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation","source_id_and_acronym":"NCT02273739","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 12/08/2014","start_date":" 12/08/2014","primary_txt":" Primary completion: 06/03/2016","primary_completion_date":" 06/03/2016","study_txt":" Completion: 06/03/2016","study_completion_date":" 06/03/2016","last_update_posted":"2021-02-23"}]